Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - norethisterone acetate; oestradiol hemihydrate; oestradiol -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

macspred pty. ltd. - glufosinate-ammonium - soluble concentrate - glufosinate-ammonium organophosphorus-phosphinic ac active 200.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; povidone; hyprolose; silicon dioxide; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - cidala is indicated for the treatment of: - erectile dysfunction (ed) in adult males; - moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; silicon dioxide; croscarmellose sodium; lactose monohydrate; sodium lauryl sulfate; povidone; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - cidala is indicated for the treatment of: - erectile dysfunction (ed) in adult males; - moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; croscarmellose sodium; magnesium stearate; povidone; hyprolose; silicon dioxide; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - cidala is indicated for the treatment of: - erectile dysfunction (ed) in adult males; - moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.35 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; shellac; ethanol absolute; iron oxide black; butan-1-ol; isopropyl alcohol; propylene glycol; purified water; titanium dioxide; brilliant blue fcf; iron oxide yellow; gelatin; sodium lauryl sulfate - treatment of major depression. treatment of obsessive compulsive disorder. treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.,the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.35 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; shellac; ethanol absolute; iron oxide black; butan-1-ol; isopropyl alcohol; propylene glycol; purified water; titanium dioxide; brilliant blue fcf; iron oxide yellow; gelatin; sodium lauryl sulfate - treatment of major depression. treatment of obsessive compulsive disorder. treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.,the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.35 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; shellac; ethanol absolute; iron oxide black; butan-1-ol; isopropyl alcohol; propylene glycol; purified water; titanium dioxide; brilliant blue fcf; iron oxide yellow; gelatin; sodium lauryl sulfate - treatment of major depression. treatment of obsessive compulsive disorder. treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.,the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.47 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 400; magnesium stearate; purified talc; hypromellose; croscarmellose sodium; titanium dioxide; colloidal anhydrous silica - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.74 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; croscarmellose sodium; macrogol 400; hypromellose; titanium dioxide; microcrystalline cellulose; magnesium stearate - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder